RTTNews | Jun 28, 2021 10:27AM EDT

10:26 Monday, June 28, 2021 (RTTNews.com) - Shares of Anavex Life Sciences Corp. (AVXL) are climbing more than 14% Monday morning after the company announced positive results from the mid-stage study of its drug candidate Anavex 2-73 in patients with Parkinson's disease dementia.

Phase 2 study of Anavex 2-73 (Blarcamesine) showed that treatment with Anavex 2-73 resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints, the company said.

AVXL touched a new high of $30.56 this morning, before slipping to trade at $28.46 currently.

Read the original article on RTTNews ( https://www.rttnews.com/3205457/anavex-life-sciences-up-on-positive-results-from-anavex-2-73-study-in-parkinson-s-disease-dementia.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved